T. Coleman

发表

Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines.

Jon Read, Andrew G. Leach, Andrew G Leach, 2008, Bioorganic & medicinal chemistry letters.

Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers.

N. Simmons, T. Coleman, I. Haslam, 2011, European journal of pharmacology.

Intestinal Ciprofloxacin Efflux: The Role of Breast Cancer Resistance Protein (ABCG2)

N. Simmons, J. Wright, T. Coleman, 2011, Drug Metabolism and Disposition.

Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).

N. Simmons, Keith Jones, T. Coleman, 2008, Biochemical pharmacology.

Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells

N. Simmons, T. Coleman, K. Jones, 2008, British journal of pharmacology.

Inhibitors of the Tyrosine Kinase EphB4. Part 3. Identification of Non-benzodioxole-Based Kinase Inhibitors.

D. Cross, B. Barlaam, R. Ducray, 2011 .

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Andrew P Thomas, C. Rooney, E. Kilgour, 2012, Cancer research.

The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes

N. Plant, A. Thumser, T. Coleman, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

Therapeutics , Targets , and Chemical Biology AZD 4547 : An Orally Bioavailable , Potent , and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Andrew P Thomas, C. Rooney, E. Kilgour, 2012 .

Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3

Andrew P Thomas, E. Kilgour, T. Klinowska, 2011 .

Microsoft Word-35644277-file00

N. Simmons, J. Wright, T. Coleman, 2011 .

In Silico and in Vitro Modeling of Hepatocyte Drug Transport Processes: Importance of ABCC2 Expression Levels in the Disposition of Carboxydichlorofluroscein

Tanya Coleman, Nick Plant, N. Plant, 2009, Drug Metabolism and Disposition.

Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.

D. Cross, B. Barlaam, R. Ducray, 2011, Bioorganic & medicinal chemistry letters.

Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.

D. Cross, B. Barlaam, R. Ducray, 2010, Bioorganic & medicinal chemistry letters.

Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue

Tanya Coleman, Chris Womack, C. Womack, 2011, Biopharmaceutics & drug disposition.

Probabilistic Orthology Analysis of the ATP-Binding Cassette Transporters: Implications for the Development of Multiple Drug Resistance Phenotype

N. Plant, C. Fisher, T. Coleman, 2012, Drug Metabolism and Disposition.

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Andrew P Thomas, C. Rooney, E. Kilgour, 2012, Cancer research.

In Silico and in Vitro Modeling of Hepatocyte Drug Transport Processes: Importance of ABCC2 Expression Levels in the Disposition of Carboxydichlorofluroscein

N. Plant, G. Gibson, T. Coleman, 2009, Drug Metabolism and Disposition.

Compartmental modelling of the pharmacokinetics of a breast cancer resistance protein

Kevin Jones, Thomas R. B. Grandjean, James W. T. Yates, 2011, Comput. Methods Programs Biomed..

Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Yi-long Wu, Jin-Ji Yang, Amir Handzel, 2016 .

Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue

C. Womack, T. Coleman, I. Haslam, 2011, Biopharmaceutics & drug disposition.